IP Library Granted Patent US 11,788,076
Granted Patent B2
US 11,788,076 · App. 16/755,074 · Granted Oct 17, 2023

Full replacement technique for T cell receptor using platinum TALEN

Inventors: Tatsuo Ichinohe (Hiroshima, JP); Takashi Yamamoto (Higashi-Hiroshima, JP); Tetsushi Sakuma (Higashi-Hiroshima, JP); Yasuko Honjo (Hiroshima, JP); Takakazu Kawase (Hiroshima, JP); Takahiko Miyama (Hiroshima, JP); Ryuji Suzuki (Ibaraki, JP)
Assignees: Hiroshima University; Repertoire Genesis Incorporation
C12N9/22C12N15/64C07K19/00C07K2319/81
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,788,076
App. No.
16/755,074
Granted
Oct 17, 2023
Kind
B2
Abstract

The present disclosure provides a technique whereby the influence of an endogenous TCR is eliminated in TCR gene transfer. A TCR gene is edited using a genome editing enzyme, said genome editing enzyme having one characteristic that amino acids at two specific positions in DNA-binding modules contained in a DNA-binding domain thereof show repeating patterns which differ from one module to another among the four DNA-binding modules. Thus, a lowering in the expression efficiency of the transferred TCR caused by mispairing with an endogenous TCR and the occurrence of a self-reactive TCR are avoided.

Claims (15)

1. A method of editing a T cell receptor (TCR) gene, comprising introducing into a T cell a composition comprising a nucleic acid encoding a polypeptide comprising a DNA binding domain and a functional domain, wherein

the DNA binding domain and the functional domain are connected by a polypeptide consisting of 35 to 55 amino acids,

the DNA binding domain comprises a plurality of DNA binding modules consecutively from the N-terminal side of the DNA binding domain,

a combination of the xth amino acid and the yth amino acid in the 4n-3th DNA binding module from the N-terminus being identical for any n,

a combination of the xth amino acid and the yth amino acid in the 4n-2th DNA binding module from the N-terminus being identical for any n,

a combination of the xth amino acid and the yth amino acid in the 4n-1th DNA binding module from the N-terminus being identical for any n, and

a combination of the xth amino acid and the yth amino acid in the 4nth DNA binding module from the N-terminus being identical for any n,

the combination of the xth amino acid and the yth amino acid in the 4n-3th DNA binding module from the N-terminus, the combination of the xth amino acid and the yth amino acid in the 4n-2th DNA binding module from the N-terminus, the combination of the xth amino acid and the yth amino acid in the 4n-1th DNA binding module from the N-terminus, and the combination of the xth amino acid and the yth amino acid in the 4nth DNA binding module from the N-terminus are different from one another, and

n is a natural number from 1 to 10, x is a natural number from 1 to 40, y is a natural number from 1 to 40, and x and y are different natural numbers, wherein the functional domain is a DNA cleaving domain, wherein the editing of a TCR gene is removal of an endogenous TCR gene, and wherein the DNA binding domain comprises the amino acid sequence of SEQ ID NO: 86, the amino acid sequence of SEQ ID NO: 87, the amino acid sequence of SEQ ID NO: 88, the amino acid sequence of SEQ ID NO: 89, the amino acid sequence of SEQ ID NO: 90, or the amino acid sequence of SEQ ID NO: 91.

2. The method of claim 1 , comprising:

introducing into a T cell the composition wherein the DNA binding domain specifically binds to a gene encoding TCRα; and

introducing into a T cell the composition wherein the DNA binding domain specifically binds to a gene encoding TCRβ.

3. The method of claim 1 , further comprising introducing an exogenous TCR gene into the T cell, thereby producing a TCR modified T cell.

4. The method of claim 3 , wherein the exogenous TCR has specificity to New York esophageal squamous cell carcinoma 1 (NY-ESO-1).

5. The method of claim 3 , further comprising the step of preparing a T cell product comprising the TCR modified T cell.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 9, 2020
From: ICHINOHE, TATSUO; YAMAMOTO, TAKASHI; SAKUMA, TETSUSHI; HONJO, YASUKO; KAWASE, TAKAKAZU; MIYAMA, TAKAHIKO
To: HIROSHIMA UNIVERSITY
Reel/Frame 053164/0739 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 9, 2020
From: SUZUKI, RYUJI
To: REPERTOIRE GENESIS INCORPORATION
Reel/Frame 053167/0615 →
Priority Claims (2)
JP 2017-197010 · Oct 10, 2017 · national
JP 2018-167954 · Sep 7, 2018 · national
Continuity (1)
Related Publication 20200362323A1 · Nov 19, 2020